Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenxoneWAR:GX1 +2.88%68 Days Inventory is 72.68 as of Mar. 2026, which is 62% above its 10-year median of 44.76. GuruFocus rates WAR:GX1 with a GF Score™ of 68/100 and a GF Value™ of zł6.48 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, Genxone ranks better than 83.7% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Genxone's Average Total Inventories for the
three
months ended in Mar. 2026 was zł0.18 Mil. Genxone's Cost of Goods Sold for the
three
months ended in Mar. 2026 was zł0.23 Mil.
Hence, Genxone's Days Inventory for the
three
months ended in Mar. 2026 was 72.68.
The historical rank and industry rank for Genxone's Days Inventory or its related term are showing as below:
WAR:GX1'
s Days Inventory Range Over the Past 10 Years
Min: 18.03 Med: 44.76 Max: 361.28
Current: 58.56
During the past 8 years, Genxone's highest Days Inventory was 361.28. The lowest was 18.03. And the median was 44.76.
WAR:GX1's Days Inventory is ranked better than 83.7% of 638
companies
in the Biotechnology industry
Industry Median: 182.94
vs WAR:GX1: 58.56
Genxone's Days Inventory
increased
from Mar. 2025 (66.70) to Mar. 2026 (72.68).
It might indicate that Genxone's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Genxone's Inventory Turnover for the
three
months ended in Mar. 2026 was 1.26.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genxone's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.37.
Genxone (WAR:GX1) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Genxone's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genxone's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Genxone Days Inventory Related Terms
Genxone Days Inventory Historical Data
* Premium members only.
The historical data trend for Genxone's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:GX1 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Genxone's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genxone Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genxone's Days Inventory distribution charts can be found below:
* The bar in red indicates where Genxone's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genxone (WAR:GX1) has a Days Inventory of 72.68 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Genxone and its competitors. This is 62% above median its historical median of 44.76. Over the past decade, Genxone's Days Inventory has ranged from 18.03 to 361.28. According to the industry distribution chart, Genxone ranks #104 out of 638 companies in the Biotechnology industry, placing it in the top 16.3%.
Is Genxone's Days Inventory too high?
Genxone's current Days Inventory of 72.68 is 62% above median its 10-year median of 44.76. Over the past 10 years, this metric has ranged from a low of 18.03 to a high of 361.28. The Biotechnology industry median Days Inventory is 182.94. Genxone's value of 72.68 is 60.3% below this industry median. Based on the distribution chart, Genxone ranks #104 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genxone has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genxone's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genxone ranks #104 out of 638 companies for Days Inventory. This places Genxone in the top 16% of its industry — outperforming the majority of peers. The industry median Days Inventory is 182.94. Genxone's value of 72.68 is 60.3% below this benchmark. Historically, Genxone's own Days Inventory has ranged from 18.03 to 361.28 over the past decade. While the company's 10-year median is 44.76 vs. the industry median of 182.94, Genxone has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 182.94, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genxone's current Days Inventory of 72.68 is 60.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Genxone and its competitors. For the Biotechnology industry, the median Days Inventory is 182.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genxone's current Days Inventory is 72.68, which is 62% above median its own 10-year median of 44.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genxone stock overvalued right now?
Based on GuruFocus' analysis, Genxone (WAR:GX1) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.48, compared to a current price of zł5.72 — trading 11.7% below its estimated fair value. The current Days Inventory is 72.68, which is 62% above median its 10-year median of 44.76 and 60.3% below the Biotechnology industry median of 182.94. Genxone's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Genxone (WAR:GX1), the current Days Inventory is 72.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genxone (WAR:GX1) Overvalued in 2026?
Based on GuruFocus' analysis, Genxone stock appears to be undervalued.
The current stock price of zł5.72 is trading 11.7% below its estimated GF Value™ of zł6.48.
GuruFocus considers Genxone to be Modestly Undervalued.
Key valuation signals for WAR:GX1:
Days Inventory: 72.68 (62% above median its 10-year median of 44.76)
GF Value™: zł6.48 vs. price of zł5.72 (11.7% below fair value)
Industry Position: 60.3% below the Biotechnology median (#104 of 638)
No single metric tells the full story. See the WAR:GX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
68GF Score
Get the complete analysis for WAR:GX1
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GX1 has been successfully added to your 
